For SCLC with high BCL-2 expression, either in mice or in cell lines, venetoclax could robustly suppress tumor survival, which provides a basis for its clinical practice in SCLC patients harboring high BCL-2 [142]. Here, BCL2 is linked to small cell lung carcinoma.